Mitochondrial dysfunction in Parkinson's disease - Revisited

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 2, 2007, Pages 150-159

  Mortiboys, Heather Jane ^a,b   Schaefer, Jochen ^a   Reichmann, Heinz ^a   Jackson, Sandra ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Complex I; Mitochondria; Parkinson's disease; Rotenone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CYTOCHROME C OXIDASE; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; NUCLEOTIDE; PARKIN; PESTICIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SERINE PROTEINASE OMI; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRANSFER RNA; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUITIN THIOLESTERASE;

CLINICAL FEATURE; CYBRID; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; FAMILY STUDY; GENE DELETION; GENE MUTATION; GENETIC CODE; GENETIC IDENTIFICATION; HUMAN; IDIOPATHIC DISEASE; MOLECULAR MECHANICS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; RARE DISEASE; RESPIRATORY CHAIN; REVIEW;

CLINICAL TRIALS; DNA, MITOCHONDRIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; MUTATION; PARKINSON DISEASE;

EID: 34248513508     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Eriksen J.L., Wszolek Z., Petrucelli L. Molecular pathogenesis of Parkinson's Disease. Arch Neurol 2005; 62: 353-357.
2. Braak H., Del Tredici K., Rüb U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
3. Taylor S.W., Fahy E., Zhang B., et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol 2003; 21: 281-286.
4. Taylor D.J., Krige D., Barnes P.R., et al. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 1994; 125: 77-81.
5. Anderson S., Bankier A.T., Barrell B.G., et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-465.
6. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 2005; 7: 1140-1149.
7. Liu Y., Fiskum G., Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002; 80: 780-787.
8. St-Pierre J., Buckingham J.A., Roebuck S.J., et al. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277: 44784-44790.
9. Chen Q., Vazquez E.J., Moghaddas S., et al. Production of reactive oxygen species by mitochondria. J Biol Chem 2003; 278: 36027-36031.
10. Muller F.L., Liu Y., Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 2004: 279: 49064-49073.
11. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide. Adv Exp Med Biol 1977; 78: 67-82.
12. Davis G.C., Williams A.C., Markey S.P., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249-254.
13. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
14. D'Amato R.J., Lipman Z.P., Snyder S.H. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 1986; 231: 987-989.
15. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci 1985; 36: 2503-2508.
16. Forno L.S., Langston J.W., DeLanney L.E. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449-455.
17. Langston J.W., Forno J.W., Tetrud J., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598-605.
18. Blum D., Torch S., Lambeng N., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65: 135-172.
19. Collins M.A., Neafsey E.J. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci Lett 1985; 55: 179-184.
20. Wakabayashi K., Totsuka Y., Fukutome K., et al. Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic beta-carbolines. Mutat Res 1997; 376: 253-259.
21. Betarbet R., Sherer T.B., MacKenzie G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-1306.
22. Sherer T.B., Kim J.H., Betarbet R., et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003; 179: 9-16.
23. Sherer T.B., Betarbet R., Testa C.M., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23: 10756-10764.
24. Schapira A.H.V., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1: 1269.
25. Schapira A.H., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-827.
26. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142-2145.
27. Mann V.M., Cooper J.M., Krige D., et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992; 115: 333-342.
28. Janetzky B., Hauck S., Youdim M.B., et al. Unaltered aconitase activity but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994; 169: 126-128.
29. Mizuno Y., Ohta S., Tanaka M., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's Disease. Biochem Biophys Res Commun 1989; 163: 1450-1455.
30. Mizuno Y., Suzuki K., Ohta S. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 1990; 96: 49-57.
31. Hattori N., Ikebe S., Tanaka M., et al. Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson's disease. Adv Neurol 1993; 60: 292-296.
32. Itoh K., Weis S., Mehraein P., et al. Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: and immunohistochemical and morphometric study. Mov Disord 1997; 12: 9-16.
33. Parker W.D. Jr, Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-723.
34. Krige D., Carroll M.T., Cooper J.M., et al. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992; 32: 782-788.
35. Yoshino H., Nakagawa-Hattori Y., Kando T., et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's Disease. J Neural Transm Park Dis Dement Sect 1992; 4: 27-34.
36. Beneke R., Strümper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson disease but normal in Parkinson-plus syndromes. Brain 1993; 116: 1451-1463.
37. Haas R.H., Nasirian F., Nakano K., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995; 37: 714-722.
38. Bravi D., Anderson J.J., Dagani F., et al. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's Disease. Mov Disord 1992; 7: 228-231.
39. Blake C.I., Spitz E., Leehey M., et al. Platelet mitochondrial respiratory chain function in Parkinson's disease. Mov Disord 1997; 12: 3-8.
40. Hanagasi H.A., Ayribas D., Baysal K., et al. Mitochondrial complex I, II/ III, and IV activities in familial and sporadic Parkinson's disease. Int J Neurosci 2005; 115: 479-493.
41. Martin M.A., Molina J.A., Jimenez-Jimenez F.J., et al. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Neurology 1996; 46: 1343-1346.
42. Barroso N., Campos Y., Huertas R., et al. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson's Disease. Clin Chem 1993: 39: 667-669.
43. Bindoff L.A., Birch-Machin M.A., Cartlidge N.E., et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991; 104: 203-208.
44. Schoffner J.M., Watts R.L., Juncos J.L., et al. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991; 30: 332-339.
45. Cardellach F., Marti M.J., Fernandez-Sola J., et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993; 43: 2258-2262.
46. Blin O., Desnuelle C., Rascol O., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 1994; 125: 95-101.
47. Wiedemann F.R., Winkler K., Lins H., et al. Detection of respiratory chain defects in cultured skin fibroblasts and skeletal muscle of patients with Parkinson's disease. Ann NY Acad Sci 1999; 893: 426-429.
48. Anderson J.J., Bravi D., Ferrari R., et al. No evidence for altered muscle mitochondrial function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56: 477-480.
49. DiDonato S., Zeviani M., Giovannini P., et al. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 1993; 43: 2262-2268.
50. Reichmann H., Janetzky B., Bishof F., et al. Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idioptahic Parkinson's syndrome. Eur Neurol 1994; 34: 263-267.
51. Taylor S.W., Fahy F., Ghosh S.S. Global organellar proteomics. Trends Biotechnol 2003; 21: 82-88.
52. Mytilineou C., Werner P., Molinari S., et al. Impaired oxidative decarboxylation of pyruvate in flbroblasts from patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 8: 223-228.
53. Winkler-Stuck K., Wiedemann F.R., Wallesch C.W., et al. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci 2004; 220: 41-48.
54. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246: 500-503.
55. Gu M., Cooper J.M., Taanman J.W., et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998; 44: 177-186.
56. Swerdlow R.H., Parks J.K., Cassarino D.S., et al. Cybrids in Alzheimer's disease: a cellular model of disease? Neurology 1997; 49: 918-925.
57. Trimmer P.A., Borland M.K., Keeney P.M., et al. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004; 88: 800-812.
58. Aomi Y., Chen C.S., Nakada K., et al. Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function. Biochem Biophys Res Commun 2001; 280: 265-273.
59. Limongelli A., Schaefer J., Jackson S., et al. Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA (Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet 2004; 41: 342-349.
60. Ozawa T, Tanaka M., Ikebe S., et al. Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun 1990; 172: 483-489.
61. Kapsa R.M., Jean-Francois M.J., Lertrit P., et al. Mitochondrial DNA polymorphism in substantia nigra. J Neurol Sci 1996; 144: 204-211.
62. Mawrin C., Kirches E., Krause G., et al. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci Lett 2004; 357: 111-114.
63. Schapira A.H., Holt I.J., Sweeney M., et al. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 1990; 5: 294-297.
64. Lestienne P., Nelson J., Riederer P., et al. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 1990; 55: 1810-1812.
65. Sandy M.S., Langston J.W., Smith M.T., et al. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson disease. Mov Disord 1993; 8: 74-82.
66. Shan D.E., Yeh S.I., Wan Y.C., et al. Absence of 4977-bp deletion of blood cell mitochondrial DNA in patients with young-onset Parkinson's disease. Acta Neurol Scand 1995; 91: 149-152.
67. Zhang J., Montine T.J., Smith M.A., et al. The mitochondrial common deletion in Parkinson's disease and related movement disorders. Parkinsonism Relat Disord 2002; 8: 165-170.
68. Gu G., Reyes P.E., Golden G.T., et al. Mitochondrial DNA deletions/ rearrangements in Parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 2002; 61: 634-639.
69. Bender A., Krishnan K.J., Morris C.M., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat Genet 2006; 38: 515-517.
70. Kraytsberg Y., Kudryavtseva E., McKee A.C., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38: 518-520.
71. Ikebe S., Tanaka M., Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 1995; 28: 281-295.
72. Kosel S., Grasbon-Frodl E.M., Mautsch U., et al. Novel mutations of mitochondrial complex I in pathologically proven Parkinson's disease. Neurogenetics 1998; 1: 197-204.
73. Grasbon-Frodl E.M., Kosel S., Sprinzl M., et al. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics 2002; 2: 121-127.
74. Autere J., Moilanen J.S., Finnila S., et al. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet 2004; 115: 29-35.
75. Smigrodzki R., Parks J., Parker W.D. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging 2004; 25: 1273-1281.
76. Parker W.D., Parks J.K. Mitochondrial ND5 mutations in diopathic Parkinson's disease. Biochem Biophys Res Commun 2005; 326: 667-669.
77. Simon D.K., Mayeux R., Marder K., et al. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology 2000; 54: 703-709.
78. Richter G., Sonnenschein A., Grunewald T., et al. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 2002; 109: 721-729.
79. Vives-Bauza C., Andreu A.L., Manfredi G., et al. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem Biophys Res Commun 2002; 290: 1593-601.
80. Simon D.K., Lin M.T., Zheng L., et al. Somatic mitochondrial mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging 2004; 25: 71-81.
81. Shoffner J.M., Brown M.D., Torroni A., et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993; 17: 171-184.
82. Brown M.D., Shoffner J.M., Kim Y.L., et al. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am J Med Genet 1996: 61: 283-289.
83. Mayr-Wohlfart U., Rodel G., Henneberg A. Mitochondrial tRNA (Gln) and tRNA (Thr) gene variants in Parkinson's disease. Eur J Med Res 1997; 2: 111-113.
84. Tan E.K., Khajavi M., Thornby J.I., et al. Variablity and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533-538.
85. Garcia-Lozano J.R., Mir P., Alberca R., et al. Mitochondrial DNA A4334G mutation in Alzheimer's and Parkinson's disease. Eur Neurol 2002; 48: 34-36.
86. Kosel S., Lucking C.B., Egensperger R., et al. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy - body parkinsonism. J Neurosci Res 1996; 44: 174-183.
87. van der Walt J.M., Nicodemus K.K., Martin E.R., et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72: 804-811.
88. Pyle A., Foltynie T., Tiangyou W., et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 2005; 57: 564-567.
89. Ross O.A., McCormack R., Maxwell L.D., et al. mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp Gerontol 2003; 38: 397-405.
90. Shimura H., Hattori N., Kubo S., et al. Familial Parkinson disease gene product, parkin is a ubiquitin ligase. Nat Genet 2000; 25: 302-305.
91. Müftüoglu M., Elibol B., Dalmizrak Ö., et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2003; 19: 544-580.
92. Palacino J.J., Sagi D., Goldberg M.S., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-18622.
93. Greene J.C., Whitworth A.J., Kuo I., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acab Sci USA 2003; 100: 4078-4083.
94. Pesah Y., Pham T., Burgess H., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004; 131: 2183-2194.
95. Greene J.C., Whitworth A.J., Andrews L.A., et al. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and mate immune responses in pathogenesis. Hum Mol Genet 2005; 14: 799-811.
96. Darios F, Corti O., Lucking C.B., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria - dependent cell death. Hum Mol Genet 2003; 12: 517-526.
97. Kuroda Y., Mitsui T., Kunishige M., et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006; 15: 883-895.
98. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
99. Spillantini M.G., Schmidt M.L., Lee V.M., et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
100. Singleton A.B., Farrer M., Johnson J., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
101. Miller D., Hague S.M., Clarimon J., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004; 62: 1835-1838.
102. Hsu L.J., Sagara Y., Arroyo A., et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157: 401-410.
103. Orth M., Tabrizi S.J., Schapira A.H., et al. Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. Neurosci Lett 2003; 351: 29-32.
104. Song D.D., Shults C.W., Sisk A., et al. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004; 186: 158-172.
105. Dauer W., Kholodilov N., Vila M., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acab Sci USA 2002; 99: 14524-14529.
106. Martin L.J., Pan Y., Price A.C., et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006; 26: 41-50.
107. Bonifati V., Rizzu P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
108. Zhang L., Shimoji M., Thomas B., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 2005; 14: 2063-2073.
109. Mitsumoto A., Nakagawa Y. DJ-1 is an indicator for exogenous reactive oxygen species elicited by endotoxin. Free Radic Res 2001; 35: 885-893.
110. Kim R.H., Smith P.D., Aleyasin H., et al. Hypersensitivity of DJ-1 deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005; 102: 5215-5220.
111. Valente E.M., Abou-Sleiman P.M., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
112. Gandhi S., Muqit M.M., Stanyer L., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006; 129: 1720-1731.
113. Clark I.E., Dodson M.W., Jiang C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-1166.
114. Park J., Lee S.B., Lee S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157-1161.
115. Zimprich A., Biskup S., Leitner P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
116. West A.B., Moore D.J., Biskup S., et al. Parkinson's disease - associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acab Sci USA 2005; 102: 16842-16847.
117. Strauss K.M., Martins L.M., Plun-Favreau H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14: 2099-2111.
118. Martins L.M., Morrison A., Klupsch K., et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24: 9848-9862.